Delivery Order SPE2DB22D1052-SPE2DB24FU9TH

Award Date 9/10/24
Potential Completion Date 9/11/24
Potential Value $3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract worth $1,889.10 to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the provision of GARDASIL 9 SYRINGE 0.5ML, a pharmaceutical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen holds with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a comprehensive range of...
The U.S. Defense Logistics Agency (DLA) awarded a $12,548 delivery order contract to AmerisourceBergen Drug Corp for the supply of GARDASIL 9 pharmaceutical syringes. This order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract has a firm...
The U.S. government's Defense Logistics Agency (DLA) Troop Support Medical awarded a $3,233.58 firm fixed price delivery order contract (SPE2DX15D3008|SPE2DX24F11HV) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of GARDASIL 9 SYRINGE 0.5ML. This delivery order is part of a broader indefinite delivery contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen Drug Corp holds with DLA to deliver pharmaceutical products and medical supplies...
The U.S. government's Defense Logistics Agency (DLA) Troop Support Medical awarded a delivery order worth $9,535.20 to AmerisourceBergen Drug Corporation's Corporate Office Division. The order is for the supply of GARDASIL 9, a 0.5 ml syringe vaccine, with a period of performance through September 6, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 that AmerisourceBergen holds with DLA Troop Support Medical for providing a comprehensive...
The U.S. Defense Logistics Agency (DLA) awarded a $9,366.31 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of GARDASIL 9 syringes. This delivery order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded by DLA to Amerisourcebergen Drug Corp to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA Troop Support Medical...
The U.S. Defense Logistics Agency (DLA) awarded a $32,103.85 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp's Corporate Office division for the supply of 4,565,218,430 units of the GARDASIL 9 vaccine syringe (0.5 mL). This delivery order falls under AmerisourceBergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025. The contract has no set-aside designation and is for the delivery of critical...
The U.S. Defense Logistics Agency (DLA) awarded a $3,087.58 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office division for the supply of 4565322699 GARDASIL 9 SYRINGE 0.5ML. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025, which enables DLA Troop Support Medical to efficiently procure a comprehensive range of pharmaceutical and medical supplies to support military healthcare...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $24,496.40 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of GARDASIL 9 SYRINGE 0.5ML. This delivery order falls under Amerisourcebergen Drug Corp's indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary contract vehicle for Amerisourcebergen to provide pharmaceutical products...
The Defense Logistics Agency (DLA) awarded a Firm Fixed Price delivery order contract worth $47,098.12 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the provision of 4564804564 - GARDASIL 9 SYRINGE 0.5ML. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a wide range of pharmaceutical products and...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $39,802.92 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide GARDASIL 9 SYRINGE 0.5ML pharmaceutical products. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract...
  • SPE2DB22D1052
    Indefinite Delivery Contract
  • SPE2DB22D1052-SPE2DB24FU9TH
    Delivery Order

The U.S. Defense Logistics Agency (DLA) has awarded a firm-fixed-price delivery order contract worth $3,021.74 to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of 4565740423 GARDASIL 9 SYRINGE 0.5ML, a pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which serves as the primary vehicle for delivering a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract has an ultimate completion date of September 11, 2024. No set-aside was used for this award.

Generated 12/10/24, 2:23 PM